Rancho Santa Fe Bio, Inc. Enters into Worldwide Exclusive License Agreement with Sanofi for Ataciguat
June 17, 2021 05:00 ET
|
Rancho Santa Fe Bio
SAN DIEGO and PARIS, June 17, 2021 (GLOBE NEWSWIRE) -- Rancho Santa Fe Bio, Inc. (“RSF Bio” or the “Company”), a San Diego, California-based clinical-stage cardiovascular platform company, today...
Adamis Highlights National Institute of Health Study Identifying Tempol as a Potential Antiviral Drug for COVID-19
June 07, 2021 07:30 ET
|
Adamis Pharmaceuticals Corporation
NIH Researchers Contend “Tempol may be a Promising Oral Antiviral Treatment for COVID-19” Research Team Intends to Conduct Additional Studies, Including a Prospective Clinical Study for Tempol in the...
Concentric Methods Wins High Recognition from KellyOCG
June 02, 2021 10:20 ET
|
Cape Fox FCG
Manassas, VA, June 02, 2021 (GLOBE NEWSWIRE) -- On May 25, 2021, Concentric Methods, LLC, a Cape Fox Corporation (CFC) subsidiary, was one of 23 suppliers recently recognized at a virtual ceremony...
AvantGen receives an award from the NIH/RADx to commercialize its anti-SARS-CoV-2 nucleocapsid antibodies for ultra-high sensitivity lateral flow assay development
May 25, 2021 06:00 ET
|
AvantGen Inc
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- AvantGen, a San Diego-based biotech, is a leader in the use of yeast display technology for human and rabbit monoclonal antibody discovery and...
Trevena Announces TRV027 Selected by NIH-Funded ACTIV Initiative For COVID-19 Trial
May 06, 2021 07:03 ET
|
Trevena Inc.
-- Vanderbilt University Medical Center (VUMC) is coordinating multiple-arm, multi-site ACTIV-4d study targeting RAAS TRV027 to be dosed in ~300 COVID-19 patients -- CHESTERBROOK, Pa., May 06,...
Trevena Reports First Quarter 2021 Results
May 06, 2021 07:00 ET
|
Trevena Inc.
-- Company reaffirms YE target of 100 formulary approvals for OLINVYK® Announces new OLINVYK clinical outcomes study to further examine potential benefit on respiratory, GI, and...
Trevena, Inc. Reports Fourth Quarter and Full Year 2020 Results
March 09, 2021 07:00 ET
|
Trevena Inc.
-- OLINVYK™ approved in U.S.; customer-facing teams now fully deployed Primary study completion for TRV027 in COVID-19 patients expected in 1H 2021 IND for TRV045 (S1P1 receptor modulator) on track...
Vir Biotechnology and GSK Provide Update on NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19
March 03, 2021 09:00 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO and LONDON, March 03, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today provided an update on the VIR-7831 (GSK4182136) arm...
Connectyx Announces Grant of Exclusive Worldwide License from National Institutes of Health for Repurposing Metformin to Treat Degenerative Eye Disease
February 04, 2021 11:17 ET
|
Connectyx Technologies Holdings Group, Inc
Boca Raton, FL, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel...
NIH and Other Independent Studies Confirm Low Levels of BioAegis’ ‘Inflammation Regulator Protein,’ Gelsolin, Associated with COVID-19 Severity
February 02, 2021 14:05 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...